Head-to-head evidence
amycretin vs VRB-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
amycretin
Developed by Novo Nordisk
NCT06064006 · Phase 2 · completed
The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.
Next expected readout: December 2027 · NCT07587710 (registry estimate)
VRB-101
Developed by Verdiva Bio
NCT07281937 · Phase 2 · completed
The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: November 2026 · NCT07553299 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · VRB-101's landscape